Skip to main content

Patrick Balthrop, Tom Erickson, Charles Powell, David U Prichard, and David McCarty

Premium

Luminex has announced that Patrick Balthrop will serve as the company’s new CEO and president. Balthrop will replace Tom Erickson, who had been serving as the company’s interim CEO and president since Sept. 2002.

Prior to his appointment with Luminex, Balthrop was the president of Fisher Healthcare, a division of Fisher Scientific International. Before that, he worked for more than 20 years with Abbott Laboratories in various leadership positions, Luminex said.

Balthrop has an MBA from the Kellogg Graduate School of Management of Northwestern University, and holds a BS in biology from Spring Hill College.


Aurora Discovery said that Charles Powell has joined the company as vice president of sales and marketing. Powell will be responsible for leading sales intitatives, forging strategic relationships with customers, and marketing the company’s microplate and microfluidic workstation products, Aurora said.

Powell has held several senior sales and marketing positions in the biotechnology industry, including 12 years in various roles at Beckman Coulter.


Invitrogen’s stockholders have named David U’Prichard to its board of directors, Invitrogen said last week.

U’Prichard currently serves as a venture partner with Apax Partners and as president of Druid Consulting. Prior to this, he was the CEO of 3-Dimensional Pharmaceuticals, overseeing the company’s IPO and eventual acquisition by Johnson and Johnson. He has also held management positions at SmithKline Beecham and ICI/Zeneca.

U’Prichard earned his PhD in pharmacology from the University of Kansas, and has held various academic appointments at Northwestern University Medical School, Johns Hopkins University, University of Maryland, and University of Pennsylvania.

Invitrogen said that David McCarty will rotate off the board of directors after having served for nearly five years.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.